Keywordsdemyelinating disease; multiple sclerosis (MS); cervical spondylotic myelopathy (CSM); Parkinson’s disease (PD); demyelination; myelopathy; outcomes; calibrated functional magnetic resonance imaging; multiple sclerosis; diagnosis; visual system; metabolism; multiple sclerosis; RNA binding protein; neurodegeneration; axonal damage; hnRNP A1; multiple sclerosis; neuromyelitis optica; aquaporin-4; myelin oligodendrocyte glycoprotein; opsonization; autoantibody; central nervous system; CNS-draining lymphatics; multiple sclerosis; immunotherapy; drug delivery; vaccine; fatigue; multiple sclerosis; diffuse tensor imaging; fatigue severity scale; deep gray matter nuclei volume; cortical thickness; ACTH; melanocortins; melanocortin receptors; multiple sclerosis; neuroprotection; oligodendroglia; repair; MS; NMOSD; clinically isolated syndrome (CIS); optic neuritis; transverse myelitis; brainstem syndrome; tumefactive demyelinating lesions; AQP4 antibodies; MOG antibodies; multiple sclerosis; MS; central memory T cells; TCM; effector memory T cells; TEM; resident memory T cells; TRM; n/a
